HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wallace Werble, Jr.

This article was originally published in The Rose Sheet

Executive Summary

Former F-D-C Reports publisher died Nov. 25 following a heart attack. He was 60. Werble, the son and namesake of F-D-C Reports Founding Editor & Publisher Wallace Werble, began his career with the company in 1968 and worked there until 1995. Following his father's death in 1976, Werble served as managing editor of "The Pink Sheet" before focusing exclusively on his role as publisher beginning in 1979. Among his accomplishments were the introduction of paid advertising, the transition to electronic publishing through third-party integrators and direct feeds to corporate networks, and live video broadcasts of FDA advisory committee meetings...

You may also be interested in...



European CHMP Opinions and MAA Updates

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.

SwedenBio Snapshot Shows Vibrant Ecosystem

Sweden´s ecosystem for drug discovery and development is flourishing, seeded by academia, nurtured by incubators and funded from varied sources, 2020 report shows.

Teva, Sandoz And Accord Take COVID-19 Action

While Teva has helped to mitigate a Canadian shortage of salbutamol inhalers, Accord has struck a deal with the UK government to supply hydroxychloroquine. Sandoz is bolstering its inventory to meet demand and Apotex is donating critical medicines, while MedPharm’s new testing model will screen drugs for therapeutic effectiveness and Beximco is focusing on manufacturing hydroxychloroquine, favipiravir and ivermectin.

UsernamePublicRestriction

Register

AP017437

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel